Charles Schwab Investment Management Inc. Has $124,000 Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)

Charles Schwab Investment Management Inc. grew its holdings in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) by 100.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 29,987 shares of the company’s stock after purchasing an additional 15,000 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Eledon Pharmaceuticals were worth $124,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Kera Capital Partners Inc. bought a new stake in Eledon Pharmaceuticals in the fourth quarter worth approximately $106,000. Inspire Investing LLC bought a new position in shares of Eledon Pharmaceuticals during the 4th quarter worth approximately $802,000. Finally, Geode Capital Management LLC grew its position in shares of Eledon Pharmaceuticals by 9.7% during the 3rd quarter. Geode Capital Management LLC now owns 378,058 shares of the company’s stock worth $942,000 after buying an additional 33,569 shares during the period. Institutional investors own 56.77% of the company’s stock.

Eledon Pharmaceuticals Trading Down 5.0 %

NASDAQ ELDN opened at $3.22 on Wednesday. The company has a market cap of $192.82 million, a P/E ratio of -1.60 and a beta of 0.80. The company has a fifty day simple moving average of $4.09 and a 200 day simple moving average of $3.91. Eledon Pharmaceuticals, Inc. has a 12-month low of $1.52 and a 12-month high of $5.54.

Eledon Pharmaceuticals (NASDAQ:ELDN) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.32). During the same quarter in the previous year, the business posted ($1.00) EPS. Sell-side analysts predict that Eledon Pharmaceuticals, Inc. will post -0.81 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Guggenheim assumed coverage on shares of Eledon Pharmaceuticals in a research report on Tuesday, January 28th. They set a “buy” rating and a $9.00 target price on the stock.

Eledon Pharmaceuticals Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).